DIAFERT - Trademark Details
Status: 602 - Abandoned-Failure To Respond Or Late Response
Image for trademark with serial number 88339989
Serial Number
88339989
Word Mark
DIAFERT
Status
602 - Abandoned-Failure To Respond Or Late Response
Status Date
2020-08-17
Filing Date
2019-03-14
Mark Drawing
4000 - Standard character mark Typeset
Attorney Name
Law Office Assigned Location Code
M60
Employee Name
CHANG, KATHERINE S
Statements
Goods and Services
Pharmaceutical preparations used in connection with anti-aging, namely, pharmaceutical preparations for use in the treatment of glabellar lines, facial wrinkles, facial asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma agents and decongestants; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; hormone replacement therapy preparations; pharmaceutical preparations for the prevention of preterm birth or pregnancy; pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; pharmaceutical preparations for the treatment and prevention of osteoporosis; pharmaceutical preparations for the treatment and prevention of endometriosis; pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; iron chelating pharmaceutical preparations; fertility enhancing pharmaceutical preparations; pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; pharmaceutical preparations and medicines for the treatment of sensory organ disorders; pharmaceutical preparations and medicines for the treatment of central nervous system disorders; pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; pharmaceutical preparations and medicines for the treatment of circulatory system disorders; pharmaceutical preparations and medicines for the treatment of cardiovascular diseases and high blood pressure; pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; pharmaceutical preparations for supporting, encouraging and promoting bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; antibiotics; antifungal preparations; antivirals; antiprotozoans, namely, pharmaceutical preparations for treating infections caused by protozoa; pharmaceutical preparations for the prevention and treatment of bacterial infections; pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS (central nervous system) disorders, neurological disorders, neurodegenerative disorders and depression; neuroprotective agent, namely, pharmaceutical preparations to help prevent or reduce damage to the brain or spinal cord; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents, namely, pharmaceutical preparations for dilating blood vessels; pharmaceutical preparations for the treatment of hypothyroidism; pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenating creams, rehydrating creams and lotions for the face and body, excluding iron preparations for pharmaceutical use and iron preparations as food supplements
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2019-04-02
Primary Code
005
Correspondences
Name
Matthew O. Brady
Address
Please log in with your Justia account to see this address.
Trademark Events
Event DateEvent Description
2019-03-18NEW APPLICATION ENTERED IN TRAM
2019-04-02NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2019-05-23ASSIGNED TO EXAMINER
2019-05-29NON-FINAL ACTION WRITTEN
2019-05-29NON-FINAL ACTION E-MAILED
2019-05-29NOTIFICATION OF NON-FINAL ACTION E-MAILED
2019-11-21TEAS RESPONSE TO OFFICE ACTION RECEIVED
2019-11-21CORRESPONDENCE RECEIVED IN LAW OFFICE
2019-11-21TEAS/EMAIL CORRESPONDENCE ENTERED
2019-12-13NON-FINAL ACTION WRITTEN
2019-12-13NON-FINAL ACTION E-MAILED
2019-12-13NOTIFICATION OF NON-FINAL ACTION E-MAILED
2019-12-17TEAS RESPONSE TO OFFICE ACTION RECEIVED
2020-01-09ASSIGNED TO LIE
2020-01-13CORRESPONDENCE RECEIVED IN LAW OFFICE
2020-01-13TEAS/EMAIL CORRESPONDENCE ENTERED
2020-02-04FINAL REFUSAL WRITTEN
2020-02-04FINAL REFUSAL E-MAILED
2020-02-04NOTIFICATION OF FINAL REFUSAL EMAILED
2020-08-17ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
2020-08-17ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND